Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer

Hideya Ohnishi, Mitsuo Katano

研究成果: ジャーナルへの寄稿記事

48 引用 (Scopus)

抄録

Pancreatic cancer is one of the most aggressive and difficult cancers to treat. Despite numerous research efforts, limited success has been achieved in the therapeutic management of patients with this disease. In the current review, we focus on one component of morphogenesis signaling, Hedgehog (Hh), with the aim of developing novel, effective therapies for the treatment of pancreatic cancer. Hh signaling contributes to the induction of a malignant phenotype in pancreatic cancer and is responsible for maintaining pancreatic cancer stem cells. In addition, we propose a novel concept linking Hh signaling and tumor hypoxic conditions, and discuss the effects of Hh inhibitors in clinical trials. The Hh signaling pathway may represent a potential therapeutic target for patients with refractory pancreatic cancer.

元の言語英語
ページ(範囲)2335-2342
ページ数8
ジャーナルWorld Journal of Gastroenterology
20
発行部数9
DOI
出版物ステータス出版済み - 1 1 2014

Fingerprint

Pancreatic Neoplasms
Therapeutics
Neoplastic Stem Cells
Morphogenesis
Neoplasms
Clinical Trials
Phenotype
Research

All Science Journal Classification (ASJC) codes

  • Gastroenterology

これを引用

Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer. / Ohnishi, Hideya; Katano, Mitsuo.

:: World Journal of Gastroenterology, 巻 20, 番号 9, 01.01.2014, p. 2335-2342.

研究成果: ジャーナルへの寄稿記事

@article{c5f0e802744c45eb90f10e78c24f2781,
title = "Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer",
abstract = "Pancreatic cancer is one of the most aggressive and difficult cancers to treat. Despite numerous research efforts, limited success has been achieved in the therapeutic management of patients with this disease. In the current review, we focus on one component of morphogenesis signaling, Hedgehog (Hh), with the aim of developing novel, effective therapies for the treatment of pancreatic cancer. Hh signaling contributes to the induction of a malignant phenotype in pancreatic cancer and is responsible for maintaining pancreatic cancer stem cells. In addition, we propose a novel concept linking Hh signaling and tumor hypoxic conditions, and discuss the effects of Hh inhibitors in clinical trials. The Hh signaling pathway may represent a potential therapeutic target for patients with refractory pancreatic cancer.",
author = "Hideya Ohnishi and Mitsuo Katano",
year = "2014",
month = "1",
day = "1",
doi = "10.3748/wjg.v20.i9.2335",
language = "English",
volume = "20",
pages = "2335--2342",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "9",

}

TY - JOUR

T1 - Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer

AU - Ohnishi, Hideya

AU - Katano, Mitsuo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pancreatic cancer is one of the most aggressive and difficult cancers to treat. Despite numerous research efforts, limited success has been achieved in the therapeutic management of patients with this disease. In the current review, we focus on one component of morphogenesis signaling, Hedgehog (Hh), with the aim of developing novel, effective therapies for the treatment of pancreatic cancer. Hh signaling contributes to the induction of a malignant phenotype in pancreatic cancer and is responsible for maintaining pancreatic cancer stem cells. In addition, we propose a novel concept linking Hh signaling and tumor hypoxic conditions, and discuss the effects of Hh inhibitors in clinical trials. The Hh signaling pathway may represent a potential therapeutic target for patients with refractory pancreatic cancer.

AB - Pancreatic cancer is one of the most aggressive and difficult cancers to treat. Despite numerous research efforts, limited success has been achieved in the therapeutic management of patients with this disease. In the current review, we focus on one component of morphogenesis signaling, Hedgehog (Hh), with the aim of developing novel, effective therapies for the treatment of pancreatic cancer. Hh signaling contributes to the induction of a malignant phenotype in pancreatic cancer and is responsible for maintaining pancreatic cancer stem cells. In addition, we propose a novel concept linking Hh signaling and tumor hypoxic conditions, and discuss the effects of Hh inhibitors in clinical trials. The Hh signaling pathway may represent a potential therapeutic target for patients with refractory pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=84895858874&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895858874&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i9.2335

DO - 10.3748/wjg.v20.i9.2335

M3 - Article

VL - 20

SP - 2335

EP - 2342

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 9

ER -